Summary
An estimated 15.5 million adults and 7 million children in the U.S. live with ADHD and depend on stimulant medications like Adderall. The FDA-declared shortage (October 2022) continues into 2025, driven by DEA production quotas, supply chain failures, and telehealth-driven demand spikes during COVID. More than 7 in 10 ADHD patients diagnosed in 2023 reported difficulty filling prescriptions.
Key Points
- Between 2012 and 2022, stimulants dispensed in the U.S. increased 57.9%; women received more stimulants than men for the first time in 2022.
- DEA classifies stimulants as Schedule II — tightly regulated production quotas that cannot be quickly redirected when disruptions occur.
- Telehealth prescriptions for Schedule II drugs surged from 1% (March 2020) to 10% (April 2020) during COVID; still elevated above pre-pandemic levels.
- FDA and DEA explicitly cannot require manufacturers to produce more or change distribution.
- In September 2024, the DEA increased production quotas for some alternatives, but shortages persisted.
- Patients face a monthly relay of administrative hurdles: 30-day prescription limits, no pharmacy transfers, doctor re-issuance required.
- Without medication: increased risk of substance abuse, accidents, impaired social/emotional behavior, and premature death per research cited.
- Counterfeit pills in illegal markets pose fentanyl contamination risk for patients seeking alternative sources.
Newsletter Angles
- The DEA’s quota system was designed to prevent abuse, but it became the mechanism for a public health failure — a structural case of over-regulation causing under-supply.
- Executive function paradox: the patients who most need help navigating a complex pharmacy/prescription system are the ones who find it hardest due to their ADHD.
- Telehealth expansion created a policy inflection point — the emergency relaxation worked, but lawmakers are now reversing it under “drug abuse” framing.
- Connects to ADHD Medication Shortage and Therapist Shortage as parallel access failures in the mental health system.
Entities Mentioned
- FDA — declared shortage October 2022; supports alternative treatment development
- DEA — sets Schedule II production quotas; central chokepoint in shortage
- American Society of Health-System Pharmacists — quoted expert on prescription barriers
Concepts Mentioned
- ADHD Medication Shortage — core topic; structural cause analysis
- Regulatory Capture vs. Regulatory Failure — DEA’s quota system as policy chokepoint
Quotes
“Living without regular access to Adderall is ‘like living neck deep in cold molasses.‘” — Reddit user
“Patients need a new prescription every 30 days. You can’t get a 90-day supply. You can’t even pay cash for a longer supply if you want to.” — Michael Ganio, ASHP
ADHD is “the most treatable chronic health disorder in the world” — Russell Barkley, psychologist; stimulants relieve 80–90% of symptoms.
Notes
Source is ADHD Advisor, a health information site — advocacy-adjacent but cites DEA/FDA/CDC data. Perspective is sympathetic to patients, not neutral analysis. DEA quota data drawn from DEA commissioned report.